Search

Displaying results 3561 - 3570 of 10000 in total
  1. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    Approximately 60% of the users who completed 12 weeks of therapy reported subjective benefits from treatment. … Vayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503].

    Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  2. Target

    Solute carrier family 22 member 16

    go.drugbank.com/bio_entities/BE0003669
    TransporterHumans

    Facilitative organic cation transporter that mediates the transport of carnitine as well as the polyamine spermidine (PubMed:12089149, PubMed:20037140). Mediates the partially Na(+)-dependent bidirectional transport of carnitine (PubMed:...

    Polypeptides: Solute carrier family 22 member 16
  3. Drug

    NKTT-120

    go.drugbank.com/drugs/DB17730
    Investigational

    NKTT-120 is a recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR).

  4. Drug

    V1003

    go.drugbank.com/drugs/DB05046
    Experimental

    Buprenorphine is a well-known analgesic and the intranasal formulation has the potential to provide a convenient alternative to other treatments, allowing patients to manage their post-operative pain both … prior to discharge from hospital and at home during their recovery period.

  5. Drug

    Phenelzine

    go.drugbank.com/drugs/DB00780
    ApprovedInvestigational

    [A15753] It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Cytochrome P-450 CYP2E1 Inducers
  6. Drug

    Poliovirus type 2 antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB10796
    ApprovedInvestigational

    Poliovirus type 2 antigen is a suspension of poliovirus Type 2 (MEF-1) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by

    Mixtures: PENTAXİM 0,5 ML IM ENJEKSİYONLUK SÜSPANSİYON İÇİN TOZ İÇEREN FLAKON VE SÜSPANSİYON İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, Td Polio Adsorbed
  7. Drug

    Istiratumab

    go.drugbank.com/drugs/DB15363
    Investigational

    Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).

  8. Drug

    Emapalumab

    go.drugbank.com/drugs/DB14724
    ApprovedInvestigational

    Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. … [L4840] As well, emapalumab was given the status of PRIME by the EMA.[L4845]

  9. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    Endogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h. … [A257464] Efanesoctocog alfa was designed to have an extended half-life, and to surpass the half-life ceiling to which other forms of recombinant FVIII are subjected due to their association with von Willebrand

  10. Drug

    Copanlisib

    go.drugbank.com/drugs/DB12483
    ApprovedInvestigational

    [A261730] Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.[A261725]

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesSynonyms: 2-AMINO-N-(7-METHOXY-8-(3-(MORPHOLIN-4-YL)PROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL(PYRIMIDINE-5-CARBOXAMIDE, 2-AMINO-N-(7-METHOXY-8-(3-MORPHOLIN-4-YLPROPOXY)-2,3-DIHYDROIMIDAZO(1,2-C)QUINAZOLIN-5-YL)PYRIMIDINE-5-CARBOXAMIDE